Abliva AB (publ) (NEVPF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 8.63 Million USD | -50.81% |
| 2022 | 17.55 Million USD | 170.63% |
| 2021 | 6.48 Million USD | -46.16% |
| 2020 | 12.04 Million USD | -24.04% |
| 2019 | 15.86 Million USD | 21.97% |
| 2018 | 13 Million SEK | -11.34% |
| 2017 | 14.66 Million SEK | -26.26% |
| 2016 | 19.89 Million SEK | -4.13% |
| 2015 | 20.74 Million SEK | -84.19% |
| 2014 | 131.26 Million SEK | 47.2% |
| 2013 | 89.17 Million SEK | 24.71% |
| 2012 | 71.5 Million SEK | 111.41% |
| 2011 | 33.82 Million SEK | -19.77% |
| 2010 | 42.15 Million SEK | 273.43% |
| 2009 | 11.28 Million SEK | -8.49% |
| 2008 | 12.33 Million SEK | 306.63% |
| 2007 | 3.03 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.9 Million USD | -27.8% |
| 2024 Q2 | 7.1 Million USD | 19.83% |
| 2023 Q2 | 13.1 Million USD | -12.74% |
| 2023 Q4 | 8.63 Million USD | -13.13% |
| 2023 FY | 8.63 Million USD | -50.81% |
| 2023 Q3 | 9.94 Million USD | -24.16% |
| 2023 Q1 | 15.02 Million USD | -14.43% |
| 2022 Q1 | 6.55 Million SEK | 0.99% |
| 2022 FY | 17.55 Million USD | 170.63% |
| 2022 Q4 | 17.55 Million USD | -3.91% |
| 2022 Q3 | 18.26 Million USD | 2.72% |
| 2022 Q2 | 17.78 Million SEK | 171.5% |
| 2021 Q1 | 15.72 Million SEK | -84.11% |
| 2021 Q2 | 21.4 Million SEK | 36.12% |
| 2021 Q3 | 11.36 Million SEK | -46.88% |
| 2021 Q4 | 6.48 Million SEK | -42.94% |
| 2021 FY | 6.48 Million USD | -46.16% |
| 2020 Q3 | 162.47 Million SEK | 1.3% |
| 2020 Q4 | 98.95 Million SEK | -39.09% |
| 2020 FY | 12.04 Million USD | -24.04% |
| 2020 Q1 | 119.89 Million SEK | -19.26% |
| 2020 Q2 | 160.39 Million SEK | 33.78% |
| 2019 Q2 | 189.76 Million SEK | -7.27% |
| 2019 FY | 15.86 Million USD | 21.97% |
| 2019 Q4 | 148.49 Million SEK | -12.75% |
| 2019 Q3 | 170.18 Million SEK | -10.32% |
| 2019 Q1 | 204.64 Million SEK | 77.48% |
| 2018 Q1 | 108.24 Million SEK | -9.88% |
| 2018 Q4 | 115.3 Million SEK | -11.09% |
| 2018 Q3 | 129.69 Million SEK | -10.46% |
| 2018 Q2 | 144.85 Million SEK | 33.82% |
| 2018 FY | 13 Million SEK | -11.34% |
| 2017 Q2 | 134.96 Million SEK | -12.86% |
| 2017 Q3 | 123.85 Million SEK | -8.24% |
| 2017 Q4 | 120.1 Million SEK | -3.02% |
| 2017 FY | 14.66 Million SEK | -26.26% |
| 2017 Q1 | 154.88 Million SEK | -14.29% |
| 2016 Q1 | 169.76 Million SEK | -2.95% |
| 2016 Q4 | 180.71 Million SEK | -6.35% |
| 2016 Q3 | 192.97 Million SEK | -14.69% |
| 2016 FY | 19.89 Million SEK | -4.13% |
| 2016 Q2 | 226.2 Million SEK | 33.25% |
| 2015 Q4 | 174.92 Million SEK | -8.47% |
| 2015 Q2 | 238.47 Million SEK | 21.27% |
| 2015 FY | 20.74 Million SEK | -84.19% |
| 2015 Q1 | 196.63 Million SEK | 49.8% |
| 2015 Q3 | 191.1 Million SEK | -19.86% |
| 2014 Q3 | 133.54 Million SEK | -2.23% |
| 2014 FY | 131.26 Million SEK | 47.2% |
| 2014 Q4 | 131.26 Million SEK | -1.71% |
| 2014 Q2 | 136.58 Million SEK | -12.35% |
| 2014 Q1 | 155.83 Million SEK | 74.75% |
| 2013 Q2 | 64.33 Million SEK | -3.11% |
| 2013 Q3 | 58.91 Million SEK | -8.43% |
| 2013 Q4 | 89.17 Million SEK | 51.37% |
| 2013 FY | 89.17 Million SEK | 24.71% |
| 2013 Q1 | 66.4 Million SEK | -7.14% |
| 2012 Q4 | 71.5 Million SEK | -1.98% |
| 2012 Q1 | 33.06 Million SEK | -2.25% |
| 2012 Q2 | 78.42 Million SEK | 137.19% |
| 2012 FY | 71.5 Million SEK | 111.41% |
| 2012 Q3 | 72.95 Million SEK | -6.98% |
| 2011 FY | 33.82 Million SEK | -19.77% |
| 2011 Q1 | 40.49 Million SEK | -3.95% |
| 2011 Q2 | 39.39 Million SEK | -2.72% |
| 2011 Q3 | 35.88 Million SEK | -8.91% |
| 2011 Q4 | 33.82 Million SEK | -5.75% |
| 2010 Q4 | 42.15 Million SEK | -2.49% |
| 2010 Q3 | 43.23 Million SEK | -5.78% |
| 2010 Q1 | 15.77 Million SEK | 39.74% |
| 2010 Q2 | 45.89 Million SEK | 190.87% |
| 2010 FY | 42.15 Million SEK | 273.43% |
| 2009 Q4 | 11.28 Million SEK | 0.0% |
| 2009 FY | 11.28 Million SEK | -8.49% |
| 2008 FY | 12.33 Million SEK | 306.63% |
| 2007 FY | 3.03 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 77.769% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -19.618% |
| SQZ Biotechnologies Company | 107.18 Million USD | 91.943% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 18.172% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 93.368% |
| Mesoblast Limited | 667.9 Million USD | 98.707% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -11834.155% |
| Genus plc | 1.02 Billion USD | 99.161% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -535.781% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1630.556% |
| Marizyme, Inc. | 22.01 Million USD | 60.772% |
| ContraFect Corporation | 20.67 Million USD | 58.237% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1277.377% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2112.322% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2159.725% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -503.07% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -108.3% |
| MultiCell Technologies, Inc. | 126.22 USD | -6842041.499% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -819.044% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 93.28% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1900.433% |
| Q BioMed Inc. | 3.51 Million USD | -145.658% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 75.451% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1020.641% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3205.362% |
| Biomind Labs Inc. | 73.81 Thousand USD | -11599.09% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 98.134% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 71.227% |
| Skye Bioscience, Inc. | 11.94 Million USD | 27.673% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -160.674% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -214.461% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -341.027% |
| IMV Inc. | 31.33 Million USD | 72.438% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1156.193% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -231.752% |
| GB Sciences, Inc. | 103.44 Thousand USD | -8248.786% |
| Alpha Cognition Inc. | 2.45 Million USD | -252.184% |
| HST Global, Inc. | 1526.00 USD | -565833.879% |
| CSL Limited | 38.02 Billion USD | 99.977% |
| Halberd Corporation | 10.13 Thousand USD | -85144.803% |
| Enzolytics Inc. | 361.7 Million USD | 97.612% |
| Resverlogix Corp. | 8.11 Million USD | -6.422% |
| Affymax, Inc. | 7.44 Million USD | -16.031% |
| SYBLEU INC | 330.46 Thousand USD | -2513.309% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -359.888% |
| argenx SE | 4.54 Billion USD | 99.81% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 69.095% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 81.896% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -37809.446% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 3.498% |
| AVAX Technologies, Inc. | 7.37 Million USD | -17.066% |
| Zenith Capital Corp. | 7410.00 USD | -116447.247% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.745% |
| Ember Therapeutics, Inc. | 184.00 USD | -4693460.326% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2583.651% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3204.262% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.065% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -496.072% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -185.484% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 83.613% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -830.659% |
| BioStem Technologies, Inc. | 14.56 Million USD | 40.687% |
| ONE Bio Corp. | 70.08 Million USD | 87.678% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -15026.197% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -373759.351% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -774.134% |
| Agentix Corp. | 261.39 Thousand USD | -3203.908% |
| LadRx Corporation | 2.3 Million USD | -274.202% |
| Cell Source, Inc. | 195.17 Thousand USD | -4324.915% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1697.113% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2342.233% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2342.233% |
| NovAccess Global Inc. | 62.24 Thousand USD | -13773.781% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1250.124% |
| Itoco Inc. | 1.4 Million USD | -516.836% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -8928.248% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -8047.312% |
| Kadimastem Ltd | 2.3 Million USD | -274.82% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -11210.673% |
| CytoDyn Inc. | 11.13 Million USD | 22.448% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5940.449% |
| Mobile Lads Corp. | 52.00 USD | -16607882.692% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -48200.621% |
| Qrons Inc. | 420.00 USD | -2056126.429% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2140.415% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1464.18% |
| Rebus Holdings, Inc. | 5000.00 USD | -172623.02% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2009.352% |
| International Stem Cell Corporation | 5.39 Million USD | -60.225% |
| Bioxytran, Inc. | 137.63 Thousand USD | -6174.54% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 42.433% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 47.909% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -10831.837% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -898.772% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -14.888% |
| Neutra Corp. | 2851.00 USD | -302816.556% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 73.35% |
| PureTech Health plc | 693.97 Million USD | 98.756% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -7.001% |
| IXICO plc | 15.84 Million USD | 45.492% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -4.276% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.642% |
| CSL Limited | 38.02 Billion USD | 99.977% |
| Cellectis S.A. | 333.99 Million USD | 97.414% |